Allergan's (NYSE:AGN) rejection of Valeant's (NYSE:VRX) newest acquisition offer has set off more speculation about the proposed transaction, with both sides ratcheting up their rhetoric. Valeant noted that the firm has "no choice but to take our offer directly to shareholders," indicating that the bid may go fully hostile, while Allergan's CEO David Pyott suggested that "The only part [of the bid] we do know how to value is the U.S. dollar portion." This highlights Allergan's general concern with Valeant's business model and claims that the company's operations are unsustainable.

In this video, from Market Checkup, the Motley Fool's health care-focused investing show, health care analysts Michael Douglass and David Williamson walk through the arguments and the next steps investors should be watching for.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need to Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.